Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 2Active not recruiting 2Unknown 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 1

Conditions

Lymphoma, T-Cell 2Immunoblastic Lymphadenopathy 2Triple Negative Breast Neoplasms 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Breast Neoplasms 1

Interventions

Etoposide 3Cyclophosphamide 3romidepsin 2pembrolizumab 2Prednisone 2Doxorubicin 2prednylidene 1fludarabine phosphate 1etoposide phosphate 1deltacortene 1Whole-Body Irradiation 1Vincristine 1Valganciclovir 1Therapeutics 1Tacrolimus 1Sirolimus 1Polymerase Chain Reaction 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1Methotrexate 1Melphalan 1Lactones 1Ganciclovir 1Foscarnet 1Flow Cytometry 1Depsipeptides 1Cyclosporine 1Clinical Trials, Phase II as Topic 1Clinical Trials, Phase I as Topic 1Cholecalciferol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Immunoblastic Lymphadenopathy × romidepsin × Clear all
NCT03278782 2026-01-09

Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
39 enrolled
DermatologicLymphoid

Immunoblastic Lymphadenopathy, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT02223208 2025-12-02

FIL_PTCL13

Fondazione Italiana Linfomi - ETS

Phase 1/2 Active not recruiting
89 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡